Jeena Sikho Lifecare Expands Nationwide with Ayurvedic Detox Kit Launch

1 min read     Updated on 14 Oct 2025, 07:22 PM
scanx
Reviewed by
Shriram ShekharScanX News Team
Overview

Jeena Sikho Lifecare Limited (JSLL) has launched its Pet Shuddhi product line nationally, introducing the Pet-Yakrit-Pleeha Shuddhi Kit, an Ayurvedic detox product for stomach, liver, and spleen. The product is available across India through JSLL's hospital network. Additionally, JSLL has entered into an exclusive diagnostic collaboration with Chandan Healthcare Limited, appointing them as the exclusive diagnostic partner for all Jeena Sikho facilities with a five-year lock-in period. This partnership aims to enhance JSLL's healthcare offerings by integrating diagnostic and preventive healthcare services.

21995532

*this image is generated using AI for illustrative purposes only.

Jeena Sikho Lifecare Limited (JSLL) has made a significant move in the Ayurvedic wellness sector with the national launch of its Pet Shuddhi product line. The company, known for its focus on Ayurvedic treatments and wellness solutions, introduced the Pet-Yakrit-Pleeha Shuddhi Kit during a press conference held in New Delhi on October 13, 2025.

Product Details

The Pet-Yakrit-Pleeha Shuddhi Kit is an Ayurvedic detox product designed to cleanse and strengthen three vital organs:

  1. Stomach
  2. Liver
  3. Spleen

This specially formulated kit aims to promote complete detoxification, helping the body maintain balance, energy, and overall health. According to the company, the product is particularly beneficial for conditions such as:

  • Gas
  • Indigestion
  • Constipation
  • Obesity
  • Liver weakness

Nationwide Availability

JSLL has made the Pet-Yakrit-Pleeha Shuddhi Kit available across India through its Jeena Sikho Hospitals Network. This move marks a significant expansion of the company's product reach and accessibility to consumers nationwide.

Market Impact

The launch of the Pet-Yakrit-Pleeha Shuddhi Kit has garnered substantial attention from both the media and the public. The event received coverage across leading newspapers and news channels, indicating strong interest in Ayurvedic wellness solutions.

Corporate Developments

In addition to the product launch, JSLL has entered into an exclusive diagnostic collaboration agreement with Chandan Healthcare Limited. This strategic partnership aims to enhance JSLL's healthcare offerings by integrating diagnostic and preventive healthcare services within its network.

Key points of the collaboration include:

  • Chandan Healthcare appointed as the exclusive diagnostic partner for all Jeena Sikho hospitals, clinics, and wellness centers
  • Five-year lock-in period for the collaboration
  • Establishment of diagnostic centers within JSLL premises by Chandan Healthcare
  • Integration of "Chandan Healthcare Cards" for patient access

This partnership is expected to improve patient experience and strengthen JSLL's position as a comprehensive healthcare and wellness service provider.

Financial Perspective

As of the latest available data, Jeena Sikho Lifecare Limited's market capitalization stands at ₹9,183.96 crore, while Chandan Healthcare Limited's market capitalization is ₹762.66 crore. This collaboration between the two companies represents a significant strategic move in the healthcare sector, potentially impacting their market positions and service offerings.

The launch of the Pet-Yakrit-Pleeha Shuddhi Kit, coupled with the strategic partnership with Chandan Healthcare, demonstrates JSLL's commitment to expanding its product portfolio and enhancing its healthcare services. These developments could potentially drive growth and increase market share for JSLL in the competitive Ayurvedic wellness and healthcare sectors.

Historical Stock Returns for Jeena Sikho Lifecare

1 Day5 Days1 Month6 Months1 Year5 Years
-4.43%-2.21%-8.32%-68.26%-53.08%+324.69%
Jeena Sikho Lifecare
View in Depthredirect
like19
dislike

Jeena Sikho Lifecare Inks 5-Year Diagnostic Deal with Chandan Healthcare, Invests ₹42.12 Crore

1 min read     Updated on 13 Oct 2025, 03:22 PM
scanx
Reviewed by
Riya DeyScanX News Team
Overview

Jeena Sikho Lifecare Limited has entered into a strategic partnership with Chandan Healthcare Limited, approved on October 13, 2025. The partnership includes a five-year exclusive diagnostic collaboration agreement and a significant investment. Chandan Healthcare will be the sole diagnostic partner for all Jeena Sikho's facilities. Jeena Sikho will invest up to ₹42.12 crore in Chandan Healthcare through convertible warrants. The collaboration aims to enhance diagnostic services quality and efficiency across Jeena Sikho's network.

21894743

*this image is generated using AI for illustrative purposes only.

Jeena Sikho Lifecare Limited has made a significant move in the healthcare sector by entering into a strategic partnership with Chandan Healthcare Limited. The collaboration, approved by Jeena Sikho's board on October 13, 2025, encompasses two major components: an exclusive diagnostic collaboration agreement and a substantial investment in Chandan Healthcare.

Strategic Partnership Details

The five-year exclusive diagnostic collaboration agreement positions Chandan Healthcare as the sole diagnostic partner for all healthcare services across Jeena Sikho's existing and future facilities. This partnership aims to enhance the quality and efficiency of diagnostic services offered to Jeena Sikho's patients.

Key aspects of the collaboration include:

Aspect Details
Duration 5-year lock-in period
Scope Diagnostic, pathological, radiological, and allied healthcare services
Chandan's Responsibilities Establish and operate diagnostic centers within Jeena Sikho's facilities
Jeena Sikho's Contributions Provide space, utilities, and brand recognition
Patient Benefits Preferential or concessional diagnostic services through Chandan Healthcare cards

Investment in Chandan Healthcare

Alongside the partnership, Jeena Sikho's board has approved a significant investment in Chandan Healthcare through a preferential issue of convertible warrants:

Investment Details Values
Number of Warrants Up to 18,00,000
Conversion Ratio 1:1 (One warrant to one equity share)
Face Value of Shares ₹10.00 per share
Issue Price per Warrant ₹234.00
Total Investment ₹42.12 crore
Initial Payment 25% at allotment
Balance Payment 75% at conversion
Conversion Period Within 18 months from allotment

Strategic Implications

This partnership and investment strategy demonstrate Jeena Sikho's commitment to enhancing its healthcare offerings. By collaborating with Chandan Healthcare, Jeena Sikho aims to provide standardized, high-quality diagnostic services across its network. The investment in Chandan Healthcare further solidifies this partnership and potentially allows Jeena Sikho to benefit from Chandan's growth in the diagnostic sector.

The move is likely to strengthen Jeena Sikho's position in the healthcare market by offering integrated services and potentially improving patient care through advanced diagnostic capabilities. It also reflects a trend in the healthcare industry towards strategic partnerships that combine complementary strengths to enhance overall service quality and operational efficiency.

As the healthcare landscape continues to evolve, such collaborations may become increasingly common, with companies seeking to create comprehensive ecosystems that can provide end-to-end patient care solutions.

Historical Stock Returns for Jeena Sikho Lifecare

1 Day5 Days1 Month6 Months1 Year5 Years
-4.43%-2.21%-8.32%-68.26%-53.08%+324.69%
Jeena Sikho Lifecare
View in Depthredirect
like19
dislike
More News on Jeena Sikho Lifecare
Explore Other Articles
736.20
-34.15
(-4.43%)